Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
Projects focusing on potential strategies that could be implemented in Europe and rolled out in low-and middle income countries to favour the improvement of quality of care for all people living with diabetes.
Característiques principals
Proposals should be consistent with at least one of these 4 areas:
  • Direct acting antivirals with data demonstrating clear differentiation from currently marketed influenza antiviral products
  • Host targeted therapies with data demonstrating clear benefit over currently marketed influenza virus therapeutics
  • Compounds that target multiple pathways or mechanisms to reduce the likelihood of resistance emergence
  • Compounds demonstrating activity against drug resistant influenza variants
    . Special consideration will be given to therapeutic modalities that are suitable for deployment in low resource settings.
    Projects that fall outside the 4 defined areas and projects on vaccines, antibody and nanobody therapy, diagnostics, clinical trials (Phase II, III, IV), formulation development, and epidemiology are excluded from the RFP and will not be considered for funding.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
    Marta López: mlopez4@imim.es Ext.: 1576
    Carol Barnwell: cbarnwell@imim.es Ext.1670
    Convocatòria (URL)
    https://novonordiskfonden.dk/en/grant/pad-antivirals-for-pandemic-influenza-request-for-proposals-2022-2023/
    Requisits
  • Applicants must be established investigators with their own line of research and must be employed for the duration of the project at the administrating institution registered in the proposal.
  • Projects can be anchored at any type of research organization, including academia, not-for profit and commercial organizations.
  • The scope of the project must be within the scientific scope of this RfP and support the PAD aspirations.
  • An applicant (i.e., the principal investigator (PI) responsible for the project and submitting the proposal) may submit only one proposal to this specific RfP. Different PI’s can be anchored at the same institution/organization. Co-applicants can be a part of more than one proposal to this RfP, and an applicant on one proposal can be a coapplicant or collaborator on other proposals.
    • Dotació
    Up to USD 10 million per grant.
    Durada
    Between 1 and 3 years.
    AVÍS IMPORTANT
    Deadline has been extended to December 14, 2022 at 2 pm CET.

    Arxius

    Arxiu
    PAD-–-Antivirals-for-pandemic-influenza-–-Request-for-proposals-2022-2023-1.pdf